SANTO Member of Polpharma Group (JSC Chimpharm) is a leading pharmaceutical company in Kazakhstan and Central Asia. With over 140 years of experience, SANTO develops, manufactures, and distributes high-quality, affordable medicines across various therapeutic areas. As part of the Polpharma Group, SANTO benefits from international expertise and investment, focusing on modernizing production, meeting Good Manufacturing Practices (GMP) standards, and expanding its product portfolio to improve public health in the region.
Serves as the central hub for strategic decision-making, manufacturing operations, research and development, and administrative functions for SANTO's activities in Kazakhstan and Central Asia.
The Shymkent facility is one of the largest pharmaceutical manufacturing plants in Central Asia, equipped with modern production lines adhering to Good Manufacturing Practices (GMP) standards. It features advanced technology for drug production and quality control.
The work culture at SANTO's headquarters emphasizes quality, innovation in pharmaceutical manufacturing, adherence to international standards driven by Polpharma Group, and a commitment to employee development and safety within a significant industrial setting.
The Shymkent headquarters is significant as it represents a major pharmaceutical manufacturing and distribution center for Kazakhstan and the wider Central Asian region, contributing to local healthcare access and economic development. It's a key asset for the Polpharma Group in this geography.
While SANTO's primary manufacturing and operational hub is in Shymkent, Kazakhstan, it serves markets across Central Asia (including Kyrgyzstan, Uzbekistan, Tajikistan, Turkmenistan, Mongolia) and exports to other CIS countries. As a member of the Polpharma Group, SANTO benefits from the group's wider international network, R&D capabilities, and market access strategies, although SANTO's direct operational presence is concentrated in Kazakhstan and neighboring Central Asian countries.
Rashidov str., 16
Shymkent
Shymkent City
Kazakhstan
Address: st. Gogol, 80, Almaty, 050012, Kazakhstan
Supports commercial operations, market access, and engagement with healthcare professionals and institutions in the Almaty region and southern Kazakhstan.
Address: st. Kunaeva 12/1, office 302, Astana, 010000, Kazakhstan
Facilitates engagement with national government bodies, regulatory authorities, and key opinion leaders based in the capital, supporting the company's strategic interests at a national level.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, SANTO' leadership includes:
SANTO has been backed by several prominent investors over the years, including:
In the past 12 months, SANTO Member of Polpharma Group saw a key leadership change with the appointment of a new General Director (CEO), Ignacy Winczakiewicz, succeeding Jiri Urbanec.
Discover the tools SANTO uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
SANTO Member of Polpharma Group likely utilizes a standard corporate email format, commonly firstname.lastname@santo.kz, for its employees. This format is typical for professional communication within the Polpharma Group and similar multinational corporations.
firstname.lastname@santo.kz
Format
example.name@santo.kz
Example
75%
Success rate
forbes.kz • October 27, 2023
SANTO Company inaugurated a new research and development (R&D) laboratory at its Shymkent plant. The lab will focus on developing new generic drugs and improving existing formulations, aligning with WHO GMP standards and enhancing local pharmaceutical innovation....more
kapital.kz • June 1, 2023
Ignacy Winczakiewicz has been appointed as the new General Director of SANTO, a leading pharmaceutical company in Kazakhstan. He succeeds Jiri Urbanec and brings extensive experience from the pharmaceutical sector....more
kursiv.media • May 15, 2023
SANTO Company reported a 25% increase in the export of its pharmaceutical products in the first quarter of 2023, expanding its reach in CIS and other international markets. This growth highlights the company's strengthening position as a key exporter in the region....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including SANTO, are just a search away.